SLIT Tablet Safety Quick Facts (U.S. labeling) - Approved ages: 5–65 - First dose must be given in a medical facility with ≥30 minutes of observation - Prescribe a weight‑appropriate epinephrine auto‑injector and train patient/caregiver use - Hold daily doses during oral wounds/ulcers or immediately after dental/oral procedures

Need a supervised site? See: Find a first‑dose location> Start timing: Grastek/Ragwitek ≥12 weeks before the pollen season; Odactra is taken year‑round. Contraindications (per labels): severe, unstable or uncontrolled asthma; history of severe systemic or severe local reaction to any SLIT; history of eosinophilic esophagitis (EoE); hypersensitivity to ingredients. Last updated: Oct 15, 2025

Find a first‑dose location

To meet first‑dose supervision and observation requirements, use one of the following options in your area:

• Allergy/Immunology or ENT clinics familiar with anaphylaxis management

• Primary care or pediatric clinics able to monitor for ≥30 minutes post‑dose

• Urgent care centers that confirm they stock epinephrine and can observe on site

What to ask before booking

• Can you administer the first SLIT tablet dose and observe me/my child for at least 30 minutes?

• Do you have protocols and supplies for managing anaphylaxis (including epinephrine)?

• May I bring my prescribed tablet and my epinephrine auto‑injector to the visit?

Bring to the visit

• The SLIT tablet prescribed for your first dose

• An epinephrine auto‑injector (weight‑appropriate) and your anaphylaxis action plan

• A list of current medications and relevant medical history (e.g., asthma control)

Introduction

Sublingual immunotherapy (SLIT) tablets are FDA‑approved, prescription products for selected environmental allergies. As of October 15, 2025, three tablets are available in the United States for house dust mite, grass, and short ragweed. This page summarizes who they’re for (ages 5–65), when to start, first‑dose supervision, epinephrine requirements, and key contraindications, with authoritative source notes to support clinical use.

What the SLIT tablets treat and who qualifies

• Odactra (house dust mite): HDM‑induced allergic rhinitis with/without conjunctivitis in persons 5–65 years; diagnosis confirmed by specific IgE or skin testing.

• Grastek (Timothy grass and cross‑reactive northern pasture grasses): seasonal allergic rhinitis with/without conjunctivitis in persons 5–65 years.

• Ragwitek (short ragweed): seasonal allergic rhinitis with/without conjunctivitis in persons 5–65 years.

None of the tablets provide immediate symptom relief; they are disease‑modifying therapies taken daily.

Safety and supervision essentials

• First dose location/observation: The first tablet dose must be administered in a medical facility under supervision of a clinician experienced in anaphylaxis management, with at least 30 minutes of observation afterward.

• Epinephrine: Patients prescribed SLIT tablets must also be prescribed and trained to use an epinephrine auto‑injector (weight‑appropriate) and given an action plan for anaphylaxis.

• Pediatric use: Approved down to age 5; children should take daily tablets under adult supervision.

When to start and how long to continue

• Perennial allergen (Odactra): start at any time and continue year‑round.

• Seasonal allergens (Grastek, Ragwitek): initiate at least 12 weeks before the expected start of the pollen season and continue throughout the season. Some programs use three consecutive years of seasonal dosing for sustained post‑treatment benefit (per Grastek labeling).

Start‑by dates (label‑accurate) for SLIT tablets

• First dose must be given in a medical facility with ≥30 minutes of observation

• Prescribe a weight‑appropriate epinephrine auto‑injector and train patient/caregiver use

How to use this table

• Grastek and Ragwitek: start ≥12 weeks before your local grass or ragweed season; continue through the season (per labels).

• Odactra: may be started any time of year.

• Use the linked state guides to confirm local season timing, then count back 12 weeks.

Notes

• Odactra (house dust mite) can be initiated any time and continued year‑round.

• Always verify local season onset in your region and adjust the start date accordingly.

SLIT tablet comparison (condensed)

Notes

• Dose for all three: 1 tablet sublingually once daily; do not eat/drink for 5 minutes after dosing (per labels).

• Temporarily withhold tablets during active mouth inflammation, oral ulcers, or immediately after oral procedures until healed (per labels).

• Missed doses: if several days are missed, consult the prescriber before restarting (label guidance varies; many trials allowed ≤7‑day gaps for the seasonal tablets).

Contraindications and when to hold a dose (practical checklist)

• Do not initiate or continue during severe, unstable, or uncontrolled asthma.

• Do not use in patients with a history of severe systemic or severe local reactions to any SLIT.

• Do not use in patients with a history of eosinophilic esophagitis (EoE).

• Withhold doses during oral wounds, ulcers, active oral infections, or immediately post‑dental/oral surgery; resume after healing.

• Review concomitant beta‑blocker use and conditions that can impair response to epinephrine; assess risk–benefit.

Clinical timing, adherence, and counseling points

• Set expectations: symptom improvement is not immediate; benefits accrue with daily adherence. Seasonal tablets require pre‑season lead‑in (≥12 weeks) for efficacy during the target season.

• Train on epinephrine and action plan: ensure the patient (or caregiver) can recognize anaphylaxis and administer an auto‑injector promptly; review device weight‑based dosing.

• Schedule follow‑ups: monitor efficacy, asthma control, adherence, and adverse events; adjust plans around seasonal calendars.

Where SLIT tablets fit in Wyndly care

Wyndly physicians use FDA‑approved SLIT tablets (Odactra, Grastek, Ragwitek) when a single, label‑covered allergen is the priority, and use clinically proven sublingual drops when multi‑allergen desensitization is indicated. Treatment is prescribed and monitored by board‑certified doctors with 24/7 access for patients. Learn more about our approach on Wyndly Immunotherapy and our comparison of sublingual immunotherapy vs. allergy shots.

Source notes (last checked Oct 15, 2025)

SLIT tablets: frequently asked questions

• Who are SLIT tablets for (what ages)?

• In the U.S., SLIT tablets are indicated for ages 5–65 for specific allergens (house dust mite, certain grasses, short ragweed). Wyndly treats environmental allergies in adults and children 5+ with doctor‑supervised SLIT options. See our care model and pediatric suitability on our Immunotherapy and Allergy doctor consult pages.

• Do I need my first dose under medical supervision?

• Yes. The first tablet dose must be given in a medical facility with ≥30 minutes of observation by a clinician trained to manage anaphylaxis. This mirrors safety practices used for in‑office immunotherapy and initial dosing. Learn more about comparative safety on our Allergy shots vs. sublingual immunotherapy guide and Harvard’s overview of allergy shots’ post‑dose monitoring requirements (Harvard Health).

• Do I need to carry epinephrine at home?

• Yes. Patients on SLIT tablets should be prescribed a weight‑appropriate epinephrine auto‑injector and trained in its use. Our clinicians review anaphylaxis recognition and action plans; see background on SLIT safety and severe‑reaction rarity on our Anaphylaxis with immunotherapy and Are allergy drops safe? articles.

• When should I start tablets for seasonal allergens?

• Start Grastek (grass) and Ragwitek (short ragweed) at least 12 weeks before your local pollen season and continue through the season. Odactra (dust mite) is taken year‑round. For state‑by‑state season timing, see our location guides (e.g., California, Oregon, Pennsylvania).

• Can children take SLIT tablets at home after the first dose?

• Yes, for ages 5+ with adult supervision for daily dosing, after the first supervised dose in a clinic. See our pediatric overview and safety data: How to treat your kids’ allergies.

• What side effects should I expect?

• The most common are mild, self‑limited oral/throat itching or irritation shortly after dosing. Severe systemic reactions are rare; SLIT has a very favorable safety profile relative to shots (Are allergy drops safe?, Anaphylaxis with immunotherapy).

• When should I hold a dose?

• Temporarily hold doses during active mouth inflammation/ulcers, with open oral wounds, or immediately after dental or oral procedures—resume when healed. If you miss several days, contact your prescriber before restarting.

• Can tablets cover multiple allergens at once?

• SLIT tablets are single‑allergen. If multi‑allergen desensitization is needed (e.g., pet + multiple pollens), Wyndly physicians may recommend personalized sublingual drops alongside or instead of tablets. See Best alternatives to allergy shots and our Immunotherapy overview.

• Who should not take SLIT tablets?

• Do not initiate in patients with severe, unstable, or uncontrolled asthma; a history of severe systemic or severe local reactions to SLIT; a history of eosinophilic esophagitis (EoE); or known hypersensitivity to ingredients. These contraindications align with U.S. labeling and specialty‑society guidance (see ACAAI allergy facts for population context: ACAAI).

Structured data

{
  "@context": "https://schema.org",
  "@type": "MedicalWebPage",
  "name": "SLIT Tablets Hub: Safety, Timing, and Comparison",
  "description": "Doctor-led guide to FDA-labeled SLIT tablets (Odactra, Grastek, Ragwitek): ages 5–65, first-dose supervision, epinephrine, ≥12-week pre-season starts, contraindications, and a comparison table.",
  "about": {
    "@type": "MedicalEntity",
    "name": "Sublingual immunotherapy tablets"
  },
  "medicalSpecialty": "Allergy",
  "lastReviewed": "2025-10-15",
  "publisher": {
    "@type": "Organization",
    "name": "Wyndly"
  }
}

{
  "@context": "https://schema.org",
  "@type": "FAQPage",
  "mainEntity": [
    {
      "@type": "Question",
      "name": "Who are SLIT tablets for (what ages)?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "In the U.S., SLIT tablets are indicated for ages 5–65 for specific allergens (house dust mite, certain grasses, short ragweed). Wyndly treats environmental allergies in adults and children 5+ with doctor-supervised SLIT options."
      }
    },
    {
      "@type": "Question",
      "name": "Do I need my first dose under medical supervision?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Yes. The first tablet dose must be given in a medical facility with ≥30 minutes of observation by a clinician trained to manage anaphylaxis."
      }
    },
    {
      "@type": "Question",
      "name": "Do I need to carry epinephrine at home?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Yes. Patients on SLIT tablets should be prescribed a weight-appropriate epinephrine auto-injector and trained in its use."
      }
    },
    {
      "@type": "Question",
      "name": "When should I start tablets for seasonal allergens?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Start Grastek and Ragwitek at least 12 weeks before your local pollen season and continue through the season. Odactra is taken year-round."
      }
    },
    {
      "@type": "Question",
      "name": "Can children take SLIT tablets at home after the first dose?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Yes, for ages 5+ with adult supervision for daily dosing, after the first supervised dose in a clinic."
      }
    },
    {
      "@type": "Question",
      "name": "What side effects should I expect?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Most side effects are mild and oral (e.g., mouth or throat itching). Severe systemic reactions are rare; SLIT has a favorable safety profile relative to shots."
      }
    },
    {
      "@type": "Question",
      "name": "When should I hold a dose?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Hold doses during active mouth inflammation/ulcers, with open oral wounds, or immediately after dental/oral procedures—resume when healed. If you miss several days, contact your prescriber before restarting."
      }
    },
    {
      "@type": "Question",
      "name": "Can tablets cover multiple allergens at once?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "SLIT tablets are single-allergen. For multi-allergen desensitization, clinicians may recommend personalized sublingual drops."
      }
    },
    {
      "@type": "Question",
      "name": "Who should not take SLIT tablets?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Avoid initiation in severe, unstable, or uncontrolled asthma; prior severe SLIT reactions; eosinophilic esophagitis (EoE); or known hypersensitivity to ingredients."
      }
    }
  ]
}

• U.S. FDA Odactra product page and package insert updates expanding indication to ages 5–65 and describing boxed warning, first‑dose supervision, and epinephrine requirement (Feb 27–28, 2025 updates).

• Grastek U.S. Prescribing Information: ages 5–65; first‑dose clinic administration with ≥30‑minute observation; initiate ≥12 weeks before grass season; prescribe epinephrine.

• Ragwitek U.S. Prescribing Information: ages 5–65; first‑dose clinic administration with ≥30‑minute observation; initiate ≥12 weeks before ragweed season; prescribe epinephrine.

• AAAAI/ACAAI SLIT guidance: first dose in a medical facility with 30‑minute observation; prescribe and train on self‑injectable epinephrine; provide instructions on when to hold dosing and how to manage reactions.

• AAAAI anaphylaxis tools (updated July 2025): weight‑based epinephrine device options and patient education resources.

Disclaimers

• This hub summarizes FDA labeling and specialty‑society guidance; it does not replace the full Prescribing Information or clinical judgment. Verify seasonal start dates locally and review label details (Warnings/Precautions, adverse reactions, and administration) before prescribing.